Pathogenesis of stroke-like episodes in MELAS: Analysis of neurovascular cellular mechanisms

Current Neurovascular Research

Volumn 2, Issue 1, 2005, Pages 29-45

  Iizuka, Takahiro ^a,b   Sakai, Fumihiko ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

MELAS; Neuronal hyperexcitability; Pathogenesis; Stroke like episodes

Indexed keywords

ANTICONVULSIVE AGENT; ARGININE; CORTICOSTEROID; CREATINE; DICHLOROACETIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; IDEBENONE; MINOCYCLINE; NICOTINAMIDE; NORPHENAZONE; RIBOFLAVIN; RNA; SCAVENGER; SUCCINIC ACID; TAURINE; TRANSFER RNA; UBIQUINONE; URIDINE; VASODILATOR AGENT; VITAMIN;

BRAIN CORTEX; CAPILLARY PERMEABILITY; CLINICAL FEATURE; CODON; DISEASE ASSOCIATION; EPILEPTIC DISCHARGE; GENE MUTATION; HEADACHE; HUMAN; HYPEREMIA; MELAS SYNDROME; NERVE EXCITABILITY; PATHOGENESIS; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; RNA TRANSLATION; RNA TRANSPORT; SEIZURE; STROKE; VASCULAR DISEASE;

BLOOD VESSELS; BRAIN; CEREBROVASCULAR ACCIDENT; HUMANS; MELAS SYNDROME; NEURONS;

EID: 26444476117     PISSN: 15672026     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567202052773544     Document Type: Review

References (157)

1. Abe, K, Matsuo, Y, Kadekawa, J, Inoue, S, Yanagihara, T. (1999) Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): evaluation by noninvasive tissue oximetry. J Neurol Sci. 162: 65-68.
2. Amagasaki, K, Shimizu, T, Suzuki, Y, Kakizawa, T. (2001) Focal hyperperfusion in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Case report. J Neurosurg. 94: 133-136.
3. Barisic, N, Bernert, G, Ipsiroglu, O, Stromberger, C, Muller, T, Gruber, S, Prayer, D, Moser, E, Bittner, RE, Stockler-Ipsiroglu, S. (2002) Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy. Neuropediatrics 33: 157-161.
4. Bataillard, M, Chatzoglou, E, Rumbach, L, Sternberg, D, Tournade, A, Laforêt P, Jardel C, Maisonobe T, Iombès A. (2001) Atypical MELAS syndrome associated with a new mitochondrial tRNA glutamine point mutation. Neurology 56: 405-407.
5. Berbel-Garcia, A, Barbera-Farre, JR, Etessam, JP, Salio, AM, Cabello, A, Gutierrez-Rivas, E, Campos, Y. (2004) Coenzyme Q 10 Improves Lactic Acidosis, Strokelike Episodes, and Epilepsy in a Patient With MELAS (Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Strokelike episodes). Clin Neuropharmacol. 27: 187-191.
6. Betts, J, Lightowlers, RN, Turnbull, DM. (2004) Neuropathological aspects of mitochondrial DNA disease. Neurochem Res. 29: 505-511.
7. Boulet, L, Karpati, G, Shoubridge, EA. (1992) Distribution and threshold expression of the tRNA(Lys) mutation in skeletal muscle of patients with myoclonic epilepsy and ragged-red fibers (MERRF). Am J Hum Genet 51: 1187-1200.
8. Breningstall, GN, Lockman, LA. (1988) Massive focal brain swelling as a feature of MELAS. Pediatr Neurol. 4: 366-370.
9. Bresolin, N, Doriguzzi, C, Ponzetto, C, Angelini, C, Moroni, I, Castelli, E, Cossutta, E, Binda, A, Gallanti, A, Gabellini, S, et al. (1990) Ubidecarenone in the treatment of mitochondrial myopathies a multicenter double-blind trial. J Neurol Sci. 100: 70-78.
10. Börner GV, Zeviani, M, Tiranti, V, Carrara, F, Hoffmann, S, Gerbitz, KD, Lochmuller, H, Pongratz, D, Klopstock, T, Melberg, A, Holme, E, Paabo, S. (2000) Decreased aminoacylation of mutant tRNAs in MELAS but not in MERRF patients. Hum. Mol. Genet. 9: 467-475.
11. Campistol, J, Chavez, B, Vilaseca, MA, Artuch, R. (2000) Antiepileptic drugs and carnitine. Rev Neurol suppl. 1: 105-109.
12. Campos, Y, Lorenzo, G, Martin, MA, Torregrosa, A, del Hoyo, P, Rubio, JC, Garcia, A, Arenas, J. (2000) A mitochondrial tRNA(Lys) gene mutation (T8316C) in a patient with mitochondrial myopathy, lactic acidosis, and stroke-like episodes. Neuromuscul Disord. 10: 493-496.
13. Campos, Y, Martin, MA, Rubio, JC, Gutierrez, del Olmo, MC, Cabello, A, Arenas J. (1997) Bilateral striatal necrosis and MELAS associated with a new T3308C mutation in the mitochondrial ND1 gene. Biophys Res Commun. 238: 323-235.
14. Canafoglia, L, Franceschetti, S, Antozzi, C, Carrara, F, Farina, L, Granata, T, Lamantea, E, Savoiardo, M, Uziel, G, Villani, F, Zeviani, M, Avanzini, G. (2001) Epileptic phenotypes associated with mitochondrial disorders. Neurology 56: 1340-1346.
15. Chen, RS, Huang, CC, Chu, NS. (1997) Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Eur Neurol. 37: 212-218.
16. Chen, X, Prosser, R, Simonetti, S, Sadlock, J, Jagiello, G, Schon, EA. (1995) Rearranged mitochondrial genomes are present in human oocytes. Am J Hum Genet. 57: 239-247.
17. Leu(UUR) mutation causes aminoacylation deficiency and concomitant reduced association of mRNA with ribosomes. J Biol Chem. 275: 19198-19209.
18. Ciafaloni, E, Ricci, E, Shanske, S, Moraes, CT, Silvestri, G, Hirano, M, Simonetti, S, Angelini, C, Donati, MA, Garcia, C, Martnuzzi, A, Mosewich, R, Servidei, S, Zammarchi E, Bonilla E, DeVivo, DC, Roland, LP, Schon, EA, Dimauro, S. (1992) MELAS: clinical features, biochemistry, and molecular genetics. Ann Neuro. 31: 391-398.
19. Clark, JM, Marks, MP, Adalsteinsson, E, Spielman, DM, Shuster, D, Horoupian, D, Albers, GW. (1996) MELAS: clinical and pathologic correlations with MRI, xenon/CT, and MR spectroscopy. Neurology 46: 223-227.
20. Cock, H, Schapira, AHV. (1999) Mitochondrial DNA mutations and mitochondrial dysfunction in epilepsy. Epilepsia 40(suppl 3): 33-40.
21. Corona, P, Antozzi, C, Carrara, F, D'Incerti, L, Lamantea, E, Tiranti, V, Zeviani, M. (2001) A novel mtDNA mutation in the ND5 subunit of complex I in two MELAS patients. Ann Neuro. 49: 106-110.
22. Cray, SH, Robinson, BH, Cox, PN. (1998) Lactic acidemia and bradyarrhythmia in a child sedated with propofol. Crit Care Med. 26: 2087-2092.
23. Crimi, M, Galbiati, S, Moroni, I, Bordoni, A, Perini, MP, Lamantea, E, Sciacco, M, Zeviani, M, Biunno, I, Moggio, M, Scarlato, G, Comi, GP. (2003) A missense mutation in the mitochondrial ND5 gene associated with a Leigh-MELAS overlap syndrome. Neurology 60: 1857-1861.
24. Cummins, JM, Wakayama, T, Yanagimachi, R. (1997) Fate of microinjected sperm components in the mouse oocyte and embryo. Zygote 5: 301-308.
25. Curran, JF. (1998) Modified nucleosides in translation. In: Modification and Editing of RNA. Grosjean, H. and Benn, R. Ed., American Society for Microbiology, Washington, DC, pp.493-516.
26. Danks, RA, Dorevitch, M, Cummins, JT, Byrne, E. (1988) Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS): adolescent onset with severe cerebral edema. Aust N Z J Med. 18: 69-72.
27. Dashe, JF, Boyer, PJ. (1998) Case records of the Massachusetts General Hospital. N Engl J Med. 339: 1914-1923.
28. De Stefano, N, Matthews, PM, Ford, B, Genge, A, Karpati, G, Arnold, DL. (1995) Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 45: 1193-1198.
29. De Toledo, M, Díaz-Guzmán, J, Pérz-Martínez, DA, Sáiz-Díaz, RA, Rodríguez-Vallejo, A, Campos, Y. (2001) MELAS syndrome masquerading as herpes encephalitis: genetic diagnosis. Rev Neurol. 33: 148-150.
30. DiMauro, S, Moraes, CT. (1993) Mitochondrial encephalomyopathies. Arch Neurol. 50: 1197-1208.
31. DiMauro, S, Schon, EA. (2003) Mitochondrial Respiratory-Chain Diseases. N Engl J Med. 348: 2656-2668.
32. Dimauro, S, Andreu, AL. (2000) Mutations in mtDNA: are we scraping the bottom of the brain? Brain Pathol. 10: 431-441.
33. Durcan, L, Carpenter, S, Shoubridge, EA. (1992) Distribution of tRNALEU mtDNA mutation in MELAS brain. Neurology 42(suppl 3): 282. Abstract.
34. El Idrissi, A, Trenkner, E. (2004) Taurine as a modulator of excitatory and inhibitory neurotransmission. Neurochem Res. 29(1): 189-197.
35. Esposito, LA, Melov, S, Panov, A, Cottrell, BA, Wallace, DC (1999) Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci USA 27: 4820-4825.
36. Feddersen, B, Bender, A, Arnold, S, Klopstock, T, Noachtar, S. (2003) Aggressive confusional state as a clinical manifestation of status epilepticus in MELAS. Neurology 61: 1149-1150.
37. Fujii, T, Okuno, T, Ito, M, Motoh, K, Hamazaki, S, Okada, S, Kusaka, H, Mikawa, H. (1990) CT, MRI, and autopsy findings in brain of a patient with MELAS. Pediatr Neurol. 6: 253-256.
38. Funakawa, I, Yasuda, T, Terao, A. (1997) Periodic lateralized epileptiform discharges in mitochondrial encephalomyopathy. Electroencephalogr Clin Neurophysiol. 103: 370-375.
39. Gervais, FG, Xu, D, Robertson, GS, Vaillancourt, JP, Zhu, Y, Huang, J, LeBlanc, A, Smith, D, Rigby, M, Shearman, MS, Clarke, EE, Zheng, H, Van Der Ploeg, LH, Ruffolo, SC, Thornberry, NA, Xanthoudakis, S, Zamboni, RJ, Roy, S, Nicholson, DW. (1999) Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97: 395-406.
40. Gilchrist, JM, Sikirica, M, Stopa, E, Shanske, S. (1996) Adult-onset MELAS. Evidence for involvement of neurons as well as cerebral vasculature in stroke like episodes. Stroke 27: 1420-1423.
41. Goto, Y, Horai, S, Matsuoka, T, Koga, Y, Nihei, K, Kobayashi, M, Nonaka I. (1992) Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology 42: 545-550.
42. Leu (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 348: 651- 653.
43. Goto, Y, Nonaka, I, Horai, S. (1991) A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Biochim Biophys Acta 1097: 238-240.
44. Leu (UUR) gene in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Biochem Biophys Res Commun. 202: 1624-1630.
45. Gropen, TI, Prohovnik, I, Tatemichi, TK, Hirano, M. (1994) Cerebral hyperemia in MELAS. Stroke 25: 1873-1876.
46. Hammans, SR, Sweeney, MG, Brockington, M, Morgan-Hughes, JA, Harding, AE. (1991) Mitochondrial encephalopathies: molecular genetic diagnosis from blood samples. Lancet 337: 1311-1313.
47. Hanna, MG, Nelson, IP, Morgan-Hughes, JA, Wood, NW. (1998) MELAS: a new disease associated mitochondrial DNA mutation and evidence for further genetic heterogeneity. J Neurol Neurosurg Psychiatry 65: 512-517
48. Hart, PE, De Vivo, DC, Schapira, AHV. (2002) Clinical features of the mitochondrial encephalomyopathies. In: Mitochondrial Disorders in Neurology 2. Schapira, AHV and Dimauro, S. Ed., Butterworth-Heinemann: Oxford, pp. 35-68.
49. Hasegawa, H, Matsuoka, T, Goto, Y, Nonaka, I. (1991) Strongly succinate dehydrogenase-reactive blood vessels in muscles from patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Ann Neuro. 29: 601-605.
50. Hattori, Y, Matsuda, M, Eizawa, T, Nakajima, K. (2001) A case of mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS), showing temporary improvement during the treatment with eicosapentaenoic acid ethyl ester. Rinsho Shinkeigaku 41: 668-672.
51. Hirano, M, Garcia-de-Yebenes, J, Jones, AC, Nishino, I, DiMauro, S, Carlo, JR, Bender, AN, Hahn, AF, Salberg, LM, Weeks, DE, Nygaard, TG. (1998) Mitochondrial neurogastrointestinal encephalopathy (MNGIE) syndrome maps to chromosome 22q13.32-qter. Am J Hum Genet. 63: 526-533.
52. Hirano, M, Pavlakis, SG. (1994) Mitochondrial myopathy, encephalopathy, lactic acidosis, and Stroke like episodes (MELAS): current concepts. J Child Neurol. 9: 4-13.
53. Hirano, M, Ricci, E, Koenigsberger, MR, Defendini, R, Pavlakis, SG, DeVivo, DC, DiMauro, S, Rowland, LP. (1992) MELAS: an original case and clinical criteria for diagnosis. Neuromuscul Disord. 2: 125-135.
54. Hirano, M, Vu, TH. (2000) Defects of intergenomic communication: Where do we stand? Brain Pathol. 1: 451-461.
55. Holt, IJ, Harding, AE, Morgan-Hughes, JA. (1988) Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 331: 717-719.
56. Holt, IJ, Harding, AE, Petty, RK, Morgan-Hughes, JA. (1990) A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Gent. 46: 428-433.
57. Iizuka, T, Sakai, F, Endo, M, Suzuki, N. (2003a) Response to sumatriptan in headache of MELAS syndrome Neurology 61: 577-578.
58. Iizuka, T, Sakai, F, Kan, S, Suzuki, N. (2003b) Slowly progressive spread of the stroke-like lesions in MELAS. Neurology 61: 1238-1244.
59. Iizuka, T, Sakai, F, Suzuki, N, Hata, T, Tsukahara, S, Fukuda, M, Takiyama, Y. (2002) Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome. Neurology 59: 816-824.
60. Ikejiri, Y, Mori, E, Ishii, K, Nishimoto, K, Yasuda, K, Sasaki, M, (1996) Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 47: 583-585.
61. Ikezoe, K, Nakagawa, M, Yan, C, Kira, J, Goto, Y, Nonaka, I. (2002) Apoptosis is suspended in muscle of mitochondrial encephalomyopathies. Acta Neuropathol (Berl.) 103: 531-540.
62. James, AM, Sheard, PW, Wei, YH, Murphy, MP. (1999) Decreased ATP synthesis is phenotypically expressed during increased energy demand in fibroblasts containing mitochondrial tRNA mutations. E u r J Biochem. 259: 462-469.
63. Kamada, K, Takeuchi, F, Houkin, K, Kitagawa, M, Kuriki, S, Ogata, A, Tashiro, K, Koyanagi, I, Mitsumori, K, Iwasaki, Y (2001) Reversible brain dysfunction in MELAS: MEG, and (1)H MRS analysis. J Neurol Neurosurg Psychiatry 70: 675-678.
64. Kaufmann, P, Shungu, DC, Sano, MC, Jhung, S, Engelstad, K. Mitsis, E, Mao, X, Shanske, S, Hirano, M, DiMauro, S, De Vivo, DC. (2004) Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 62: 1297-1302.
65. Keep, RF, Xiang, J, Bets, AL. (1993) Potassium transport at the blood brain and blood-CF barriers. In: Frontiers in cerebral vascular biology: transport and its regulation. Drewes LR, Bets AL. Edi., Plenum Press: New York, pp.43-54.
66. Kim, IO, Kim, JH, Kim, WS, Hwang, YS, Yeon, KM, Han, MC. (1996) Mitochondrial myopathy-encephalopathy-lactic acidosis-and strokelike episodes (MELAS) syndrome: CT and MR findings in seven children. Am J Roentgenol. 166: 641-645.
67. Klopstock, T, Querner, V, Schmidt, F, Gekeler, F, Walter, M, Hartard, M, Henning, M, Gasser, T, Pongratz, D, Straube, A, Dieterich, M, Muller-Felber, W. (2000) A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 55: 1748-1751.
68. Kobayashi, Y, Momoi, MY, Tominaga, K, Shimoizumi, H, Nihei, K, Yanagisawa, M, Kagawa, Y, Ohta, S. (1991) Respiration-deficient cells are caused by a single point mutation in the mitochondrial tRNA-Leu (UUR) gene in mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Am J Hum Genet. 49: 590-599.
69. Koga, Y, Ishibashi, M, Ueki, I, Yatsuga, S, Fukiyama, R, Akita, Y, Matsuishi, T. (2002) Effects of L-arginine on the acute phase of strokes in three patients with MELAS. Neurology 58: 827-828.
70. Kolb, SJ, Costello, F, Lee, AG, White, M, Wong, S, Schwartz, ED, Messe, SR, Ellenbogen, J, Kasner, SE, Galetta, SL. (2003) Distinguishing ischemic Stroke from the stroke-like lesions of MELAS using apparent diffusion coefficient mapping. J Neurol Sci. 216: 11-15.
71. Komura, K, Hobbiebrunken, E, Wilichowski, EK, Hanefeld, FA. (2003) Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr Neurol. 28: 53-58.
72. Ile reduce precursor 3′ end processing efficiency in vitro. Nucl. Acids Res. 31: 1904-1912.
73. Leu(UUR) leads to reduced 3′-end processing and CCA addition. J Mol Biol. 337: 535-544.
74. Li, M, Ona, VO, Guegan, C, Chen, M, Jackson-Lewis, V, Andrews, LJ, Olszewski, AJ, Stieg, PE, Lee, JP, Przedborski, S, Friedlander, RM. (2000) Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288: 335-339.
75. Liolitsa, D, Rahman, S, Benton, S, Carr, LJ, Hanna, MG. (2003) Is the mitochondrial complex I ND5 gene a hot-spot for MELAS causing mutations? Ann Neuro. 53: 128-132.
76. Liu, CY, Lee, CF, Hong, CH, Wei, YH. (2004) Mitochondrial DNA mutation and depletion increase the susceptibility of human cells to apoptosis. Ann N Y Acad Sci. 1011: 133-145.
77. Love, S, Nicoll, JA, Kinrade, E. (1993) Sequencing and quantitative assessment of mutant and wild-type mitochondrial DNA in paraffin sections from cases of MELAS. J Pathol 170: 9-14.
78. Macmillan, C, Lach, B, Shoubridge, EA. (1993) Variable distribution of mutant mitochondrial DNAs (tRNALeu[3243]) in tissues of symptomatic relatives with MELAS: the role of mitotic segregation. Neurology 43: 1586-1590.
79. Majamaa, K, Rusanen, H, Remes, AM, Pyhtinen, J, Hassinen, IE. (1996) Increase of blood NAD+ and attenuation of lactacidemia during nicotinamide treatment of a patient with the MELAS syndrome. Life Sci. 58: 691-699.
80. Manfredi, G, Schon, EA, Moraes, CT, Bonilla, E, Berry, GT, Sladky, JT, DiMauro S. (1995) A new mutation associated with MELAS is located in a mitochondrial DNA polypeptide-coding gene. Neuromuscul Disord. 5: 391-398.
81. Matthews, RT, Yang, L, Browne, S, Baik, M, Beal, MF. (1993) Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 43: 884-890.
82. Melone, MA, Tessa, A, Petrini, S, Lus, G, Sampaolo, S, di Fede, G, Santorelli, FM, Cotrufo, R. (2004) Revelation of a new mitochondrial DNA mutation (G12147A) in a MELAS/MERFF phenotype. Arch Neurol. 61: 269-272.
83. Menotti, F, Brega, A, Diegoli, M, Grasso, M, Modena, MG, Arbustini, E. (2004) A novel mtDNA point mutation in tRNA(Val) is associated with hypertrophie cardiomyopathy and MELAS. Ital Heart J. 5: 460-465.
84. Mirabella, M, Di Giovanni, S, Silvestri, G, Tonali, P, Servidei, S. (2000) Apoptosis in mitochondrial encephalomyopathies with mitochondrial DNA mutations: a potential pathogenic mechanism. Brain 123: 93-104.
85. Miyamoto, A, Oki, J, Takahashi, S, Itoh, J, Kusunoki, Y, Cho, K. (1997) Serial imaging in MELAS. Neuroradiology 39: 427-430.
86. Mizukami, K, Sasaki, M, Suzuki, T, Shiraishi, H, Koizumi, J, Ohkoshi, N, Ogata, T, Mori, N, Ban, S, Kosaka, K. (1992) Central nervous system changes in mitochondrial encephalomyopathy: light and electron microscopic study. Acta Neuropathol. 83: 449-452.
87. Molnár, MJ, Valikovics, A, Molnár, S, Tron, L, Dioszeghy, P, Mechler, F, Gulyas, B. (2000) Cerebral blood flow and glucose metabolism in mitochondrial disorders. Neurology 55: 544-548.
88. Montagna, P, Gallassi, R, Medori, R, Govoni, E, Zeviani, M, DiMauro, S, Lugaresi, E, Andermann, F. (1988) MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. Neurology 38: 751-754.
89. Moraes, CT, Shanske, S, Tritschler HJ, Aprille, JR, Andreetta, F, Bonilla, E, Schon, EA, DiMauro, S. (1991) MtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. Am J Hum Genet. 48: 492-501.
90. Morgan-Hughes, JA, Hanna, MG. (1999) Mitochondrial encephalomyopathies: the enigma of genotype versus phenotype. Biochem Biophys Acta 1410: 125-145.
91. Morten, KJ, Cooper, JM, Brown, GK, Lake, BD, Pike, D, Poulton, J. (1993) A new point mutation associated with mitochondrial encephalomyopathy. Hum Mol Genet. 2: 2081-2087.
92. Moudy, AM, Handran, SD, Goldberg, MP, Ruffin, N, Karl, I, Kranz-Eble, P, DeVivo, DC, Rothman, SM. (1995) Abnormal calcium homeostasis and mitochondrial polarization in a human encephalomyopathy. Proc Natl Acad Sci USA 92: 729-33.
93. Möler, HE, Wiedermann, D, Kurlemann, G, Hilbich, T, Schuierer, G. (2002) Application of NMR spectroscopy to monitoring MELAS treatment: a case report. Muscle Nerve 25: 593-600.
94. Mörl, M, Marchfelder, A. (2001) The final cut. The importance of tRNA 3′-processing. EMBO Rep. 2: 17-20.
95. Nakamura, M, Nakano, S, Goto, Y, Ozawa, M, Nagahama, Y, Fukuyama, H, Akiguchi, I, Kaji, R, Kimura, J. (1995) A novelpoint mutation in the mitochondrial tRNA(Ser(UCN)) gene detected in a family with MERRF/MELAS overlap syndrome. Biochem Biophys Res Commun. 214: 86-93.
96. Napolitano, A, Salvetti, S, Vista, M, Lombardi, V, Siciliano, G, Giraldi, C. (2000) Long-term treatment with idebenone and riboflavin in a patient with MELAS. Neurol Sci. 21(5 Suppl): S981-982.
97. Nishino, I, Komatsu, M, Kodama, S, Horai, S, Nonaka, I, Goto, Y. (1996) The 3260 mutation in mitochondrial DNA can cause mitochondrial myopathy, encephalopathy, lactic acidosis, and Stroke like episodes (MELAS). Muscle Nerve 19: 1603-1604.
98. Oguro, H, Iijima, K, Takahashi, K, Nagai, A, Bokura, H, Yamaguchi, S, Kobayashi, S. (2004) Successful treatment with succinate in a patient with MELAS. Intern Med. 43: 427-431.
99. Ohama, E, Ohara, S, Ikuta, F, Tanaka, K, Nishizawa, M, Miyatake, T. (1987) Mitochondrial angiopathy in cerebral blood vessels of mitochondrial encephalomyopathy. Acta Neuropathol. 74: 226-233.
100. Ohshita, T, Oka, M, Imon, Y, Watanabe, C, Katayama, S, Yamaguchi, S, Kajima, T, Mimori, Y, Nakamura, S. (2000) Serial diffusion-weighted imaging in MELAS. Neuroradiology 42: 651-656.
101. Okatani, Y, Wakatsuki, A, Enzan, H, Miyahara, Y. (2003) Edaravone protects against ischemia/reperfusion-induced oxidative damage to mitochondria in rat liver. Eur J Pharmacol. 465: 163-170.
102. Oldendolf, WH, Cornford, ME, Brown, WJ. (1977) The large apparent work capability of the blood-brain barrier: a study of the mitochondrial mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neuro. 1: 409-417.
103. Ona, VO, Li, M, Vonsattel, JP, Andrews, LJ, Khan, SQ, Chung, WM, Frey, AS, Menon, AS, Li, XJ, Stieg, PE, Yuan, J, Penney, JB, Young, AB, Cha, JH, Friedlander, RM. (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399: 263-267.
104. Oppenheim, C, Galanaud, D, Samson, Y, Sahel, M, Dormont, D, Wechsler, B, Marsault, C. (2000) Can diffusion weighted magnetic resonance imaging help differentiate Stroke from stroke-like events in MELAS? J Neurol Neurosurg Psychiatry 69: 248-250.
105. Park, H, Davidson, E, King, MP. (2003) The pathogenic A3243G mutation in human mitochondrial tRNALeu(UUR) decreases the efficiency of aminoacylation. Biochemistry 42: 958-64.
106. Pavlakis, SG, Kingsley, PB, Kaplan, GP, Stacpoole, PW, O'Shea, M, Lustbader, D. (1998) Magnetic resonance spectroscopy: use in monitoring MELAS treatment. Arch Neurol. 55: 849-852.
107. Pavlakis, SG, Phillips, PC, Dimauro, S, De Vivo, DC, Rowland, LP. (1984) Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes: A distinctive clinical syndrome. Ann Neuro. 16: 481-488.
108. Penn, AM, Lee, JW, Thuillier, P, Wagner, M, Maclure, KM, Menard, MR, Hall, LD, Kennaway, NG. (1992) MELAS syndrome with mitochondrial tRNALeu(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavine. Neurology 42: 2147-2152.
109. Pitkanen, S, Robinson, BH. (1996) Mitochondrial complex I deficienc leads to increased production of superoxide radicals and induction of superoxide dismutase. J Clin Invest. 98: 45-351.
110. Pénisson-Besnier, I, Reynier, P, Asfar P, Douay O, Sortais, A, Dubas, F, Emile, J, Malthiery, Y. (2000) Recurrent brain hematomas in MELAS associated with an ND5 gene mitochondrial mutation. Neurology 55: 317-318.
111. Rajesh, KG, Sasaguri, S, Suzuki, R, Maeda, H. (2003) Antioxidant MCI-186 inhibits mitochondrial permeability transition pore and upregulates Bcl-2 expression. Am J Physiol Heart Circ Physiol. 285: H2171-H2178.
112. Ravn, K, Wibrand, F, Hansen, FJ, Horn, N, Rosenberg, T, Schwartz, M. (2001) An mtDNA mutation, 14453G→A, in the NADH dehydrogenase subunit 6 associated with severe MELAS syndrome. Eur J Hum Genet. 9: 805-809.
113. Remes, AM, Liimatta, EV, Winqvist, S, Tolonen, U, Ranua, JA, Reinikainen, K, Hassinen, IE, Majamaa, K. (2002) Ubiquinone and nicotinamide treatment of patients with the 3243A→G mtDNA mutation. Neurology 59: 1275-1277.
114. Rossi, FH, Okun, M, Yachnis, A, Quisling, R, Triggs, WJ (2002) Corticosteroid treatment of mitochondrial encephalomyopathies. Neurologist 8: 313-315.
115. Rossmanith, W, Karwan, RM. (1998) Impairment of tRNA processing by point mutations in mitochondrial tRNALeu(UUR) associated with mitochondrial diseases. FEBS Letters 433: 269-274.
116. Saitoh, S, Momoi, MY, Yamagata, T, Mori, Y, Imai, M. (1998) Effects of dichloroacetate in three patients with MELAS. Neurology 50: 531-534.
117. Sakuta, R, Honzawa, S, Murakami, N, Goto, Y, Nagai, T (2002) Atypical MELAS associated with mitochondrial tRNA(Lys) gene A8296G mutation. Pediatr Neurol. 27: 397-400.
118. Sakuta, R, Nonaka I. (1989) Vascular involvement in mitochondrial myopathy. Ann Neuro. 25: 594-601.
119. Sano, M, Ishii, K, Momose, Y, Uchigata, M, Senda, M. (1995) Cerebral metabolism of oxygen and glucose in a patient with MELAS syndrome. Acta Neurol Scand. 92: 497-502.
120. Santorelli, FM, Tanji, K, Kulikova, R, Shanske, S, Vilarinho, L, Hays, AP, DiMauro, S. (1997) Identification of a novel mutation in the mtDNA ND5 gene associated with MELAS. Biochem Biophys Res Commun. 238: 326-328.
121. Leu (UUR) mutation at 3256 associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like symptoms. Biochem Mol Biol Intern. 133: 1055-1061.
122. Satoh, M, Kuroiwa, T. (1991) Organization of multiple nucleiotides and DNA molecules in mitochondria of a human cell. Exp Cell Res. 196: 137-140.
123. Scarabelli, TM, Stephanou, A, Pasini, E, Gitti, G, Townsend, P, Lawrence, K, Chen-Scarabelli, C, Saravolatz, L, Latchman, D, Knight, R, Gardin, J. (2004) Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J m Coll Cardiol. 43: 865-874.
124. Schon, EA, DiMauro, S. (2003) Medicinal and genetic approaches to the treatment of mitochondrial disease. Curr Med Chem. 10: 2523-2533.
125. Schon, EA, Hirano, M, DiMauro, S. (1994) Mitochondrial encephalomyopathies: clinical and molecular analysis. J Bioenerg Biomembr. 26: 291-299.
126. Schwartz, M, Vissing, J. (2002) Paternal inheritance of mitochondrial DNA. N Engl J Med. 347: 576-580.
127. Schürer, H, Schiffer, S, Marchfelder, A, Mörl, M. (2001) This is the end: processing, editing and repair at the tRNA 3′-terminus. Biol Chem. 382: 1147-1156.
128. Sciacco, M, Fagiolari, G, Lamperti, C, Messina, S, Bazzi, P, Napoli, L, Chiveri, L, Prelle, A, Comi, GP, Bresolin, N, Scarlato, G, Moggio, M. (2001). Lack of apoptosis in mitochondrial Encephalomyopathies. Neurology 56: 1070-1074.
129. (leu)(UUR) gene (A3243T). Biochem Biophys Res Commun. 233: 637-639.
130. Shoffner, JM, Fernhoff, PM, Krawiecki, NS, Caplan, DB, Holt, PJ, Koontz, DA, Takei, Y, Newman, NJ, Ortiz, RG, Polak, M. (1992) Subacute necrotizing encephalopathy: oxidative phosphorylation defects and the ATPase 6 point mutation. Neurology 42: 2168-2174.
131. Sparaco, M, Bonilla, E, Dimauro, S, Powers, JM. (1993) Neuropathology of mitochondrial encephalopathies due to mitochondrial DNA defects. J Neuropathol Exp Neurol. 52: 1-10.
132. Sue, CM, Crimmins, DS, Soo, YS, Pamphlett, R, Presgrave, CM, Kotsimbos, N, Jean-Francois, MJ, Byrne, E, Morris, JG. (1998) Neuroradiological features of six kindreds with MELAS tRNA(Leu) A3243G point mutation: implications for pathogenesis. J Neurol Neurosurg Psychiatry 65: 233-240.
133. Sue, CM, Shon, EA. (2000) Mitochondrial respiratory chain diseases and mutations in nuclear DNA: a promising start? Brain Pathol. 10: 442-450.
134. Suzuki, T, Suzuki, T, Wada, T, Saigo, K, Watanabe, K. (2001) Novel taurine-containing uridine derivatives and mitochondrial human diseases. Nucleic Acids Res Suppl. 1: 257-258.
135. Suzuki, T, Suzuki, T, Wada, T, Saigo, K, Watanabe, K. (2002) Taurine as a constituent of mitochondrial tRNAs: new insights into the functions of taurine and human mitochondrial diseases. EMBO J. 21: 6581-6589.
136. Takahashi, S, Tohgi, H, Yonezawa, H, Obara, S, Nagane, Y. (1998) Cerebral blood flow and oxygen metabolism before and after a stroke-like episode in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). J Neurol Sci. 158: 58-64.
137. Tanji, K, Kunimatsu, T, Vu, TH, Bonilla, E. (2001) Neuropathological features of mitochondrial disorders. Semin Cell Dev Biol. 12: 429-439.
138. Tarnopolsky, MA, Martin, J. (1999) Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 52: 854-857.
139. Tarnopolsky, MA, Roy, BD, Mac Donald, JR. (1997) A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 20: 1502-1509.
140. Taylor, RW, Chinnery, PF, Haldane, F, Morris, AA, Bindoff, LA, Wilson, J, Turnbull, DM.. (1996) MELAS associated with a mutation in the valine transfer RNA gene of mitochondrial DNA. Ann Neuro. 40: 459-462.
141. Thambisetty, M, Newman NJ. (2004) Diagnosis of management of MELAS. Expert Rev Mol Diagn. 4 (5): 631-644.
142. Tikka, T, Fiebich, BL, Goldsteins, G, Keinanen, R, Koistinaho, J. (2001) Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 21: 2580-2588.
143. Toyoda, K, Fujii, K, Kamouchi, M, Nakane, H, Arihiro, S, Okada, Y, Ibayashi, S, Iida, M. (2004) Free radical scavenger, edaravone, in Stroke with internal carotid artery occlusion. J Neurol Sci. 15; 221: 11-7.
144. Umaki, Y, Mitsui, T, Endo, I, Akaike, M, Matsumoto, T. (2002) Apoptosis-related changes in skeletal muscles of patients with mitochondrial diseases. Acta Neuropathol. (Berl.) 103: 163-170.
145. Valanne L, Paetau A, Suomalainen A, Ketonen L, Pihko H. (1996) Laminar cortical necrosis in MELAS syndrome: MR and neuropathological observations. Neuropediatrics 27: 154-160.
146. Veggiotti, P, Colamaria, V, Dalla Bernardina, B, Martelli, A, Mangione, D, Lanzi, G. (1995) Epilepsia partial is continua in a case of MELAS: clinical and neurophysiological study. Neurophysiol Clin. 25: 158-166.
147. Wallace, DC, Singh, G, Lott, MT, Hodge, JA, Schurr, TG, Lezza, AM, Elsas, LJ 2nd, Nikoskelainen, EK. (1998) Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 242: 1427-1430.
148. Wallace, DC. (1992) Diseases of the mitochondrial DNA. Annu Rev Biochem. 61: 1175-212.
149. Watanabe, Y, Hashikawa, K, Moriwaki, H, Oku, N, Seike, Y, Kodaka, R, Ono, J, Uehara, T, Kusuoka, H, Nishimura, T. (1998) SPECT findings in mitochondrial encephalomyopathy. J Nucl Med. 39: 961-964.
150. Welch, KM. (2003) Contemporary concepts of migraine. Neurology 61 (Suppl 4): S2-8.
151. Wilichowski, E, Pouwels, PJ, Frahm, J, Hanefeld, F. (1999) Quantitative proton magnetic resonance spectroscopy of cerebral metabolic disturbances in patients with MELAS. Neuropediatrics 30: 256-263.
152. Yasukawa, T, Suzuki, T, Ishii, N, Ohta, S, Watanabe, K. (2001) Wobble modification defect in tRNA disturbs codon-anticodon interaction in a mitochondrial disease. EMBO J. 20: 4794-4802.
153. (Lys) with the MERRF encephalomyopathy pathogenic mutation. FEBS Lett. 467: 175-178.
154. Yasukawa, T, Suzuki, T, Ueda, T, Ohta, S, Watanabe, K. (2000b). Modification defect at anticodon wobble nucleotide of mitochondrial tRNAsLeu(UUR) with pathogenic mutations of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. J Biol Chem. 275: 4251-4257.
155. Yoneda, M, Maeda, M, Kimura, H, Fujii, A, Katayama, K, Kuriyama, M. (1999) Vasogenic edema on MELAS: A serial study with diffusion-weighted MR imaging. Neurology 53: 2182-2184.
156. Yonemura, K, Hasegawa, Y, Kimura, K, Minematsu, K, Yamaguchi, T. (2001) Diffusion-weighted MR imaging in a case of mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. AJNR Am J Neuroradiol. 22: 269-272.
157. Zeviani, M, Muntoni, F, Savarese, N, Serra, G, Tiranti, V, Carrara, F, Mariotti, C, DiDonato, S. (1993) A MERRF/MELAS overlap syndrome associated with a new point mutation in the mitochondrial DNA tRNA(Lys) gene. Eur J Hum Genet. 1: 80-87.